Today: 23 April 2026
QBE share price jumps 7% after FY25 profit beat, dividend hike and Swiss Re deal — what’s next
20 February 2026
2 mins read

QBE share price jumps 7% after FY25 profit beat, dividend hike and Swiss Re deal — what’s next

Sydney, Feb 20, 2026, 17:34 AEDT — After-hours

  • QBE jumped 7.1%, settling at A$21.48, after the insurer delivered better-than-expected full-year numbers and lifted its final dividend.
  • The group has also struck a deal to offload its global trade credit and surety business, handing it over to Swiss Re Corporate Solutions.
  • Attention turns to March dividend dates next, with QBE’s AGM and first-quarter update lined up for May.

QBE Insurance Group (ASX:QBE) shares climbed 7.1% to finish at A$21.48 on Friday. The insurer turned in a stronger full-year profit and bumped up its dividend.

Investors have been edgy over claims costs—natural catastrophes in particular—and the effect on insurers’ margins hasn’t gone unnoticed. QBE’s release drops right in the thick of Australia’s reporting season, a period where capital strength and dividend moves can swing prices sharply.

Insurers are still adjusting their portfolios to manage volatility. QBE’s specialty unit sale fits the pattern. Now, the focus shifts to where the proceeds go: reinvestment, returns to shareholders, or cost cuts.

QBE posted a statutory net profit after tax of US$2.157 billion for 2025, with adjusted net profit reaching US$2.132 billion. Premium growth and higher investment income played a role. The combined operating ratio dropped to 91.9% from last year’s 93.1%. Net catastrophe claims ended up at US$751 million, well under the US$1.16 billion allowance. The insurer announced a final dividend of 78 Australian cents per share, bringing the total for the year to 109 cents. Guidance for 2026 remains unchanged: a combined operating ratio around 92.5% and mid-single-digit premium growth. “QBE delivered strong performance in 2025, exceeding our financial plan,” CEO Andrew Horton said. ASX Announcements

The shares jumped up to 8.5% to hit A$21.76 early on—a level not seen since early September—but later slipped from those highs by the close.

QBE rolled out its results and, at the same time, announced a deal to sell its Global Trade Credit and Surety business to Swiss Re Corporate Solutions. The transaction leaves out its French Bonds operation. “Our decision to divest … enables the reallocation of capital and resources towards growth opportunities,” said Horton. QBE Australia Pacific CEO Sue Houghton pointed to Swiss Re’s “fresh perspective and strong intent.” QBE DEV

Swiss Re said the acquired business should bring in around US$200 million a year in revenue, broadening its credit and surety offering. “This acquisition marks an important milestone,” Swiss Re Corporate Solutions CEO Ivan Gonzalez said. He noted financial terms weren’t being released, and said the deal still needs several months for approvals. swissre.com

Nigel Pittaway at Citi described QBE’s numbers as “a strong result,” highlighting gains in premiums and a combined operating ratio that beat forecasts—despite pressure from commissions and expenses. News.com.au

But this is insurance—surprises tend to show up. A tougher stretch for catastrophe losses, increased pricing pressure in crowded market segments, or sluggish investment performance could sap earnings strength and put the sustainability of that dividend boost in question.

QBE shares are set to trade ex-dividend on March 5. Investors on the books by March 6 will be eligible for the final payout, which lands April 17. Then on May 8, shareholders can expect both the AGM and the first-quarter update.

Stock Market Today

  • ARS Pharmaceuticals (SPRY) Jumps 7.1% on FDA Nod and Strong Earnings Outlook
    April 23, 2026, 10:39 AM EDT. ARS Pharmaceuticals shares surged 7.1% to $8.40 on higher investor interest following FDA approval of expanded use for its lead product, neffy. The drop in minimum age restrictions allows its use in children and adults weighing at least 33 lbs for severe allergic reactions. The company anticipates a quarterly loss of 50 cents per share, improving 42.9% year-over-year, with revenues expected to increase 180.4% to $22.35 million. Earnings estimate revisions have been positive, with a 4.6% rise in the past month, often a signal of short-term price gains. ARS carries a Zacks Rank #3 (Hold). Aurinia Pharmaceuticals, a peer in the medical-drugs sector, also rose 3.8% recently amid improving earnings forecasts.

Latest article

Google Stock Gets Fresh AI Catalyst as Alphabet Unveils Agents, Chips Before Earnings

Google Stock Gets Fresh AI Catalyst as Alphabet Unveils Agents, Chips Before Earnings

23 April 2026
Alphabet Class A shares traded near $340 Thursday morning, valuing the company at about $4.1 trillion after Google unveiled new enterprise AI software and custom chips at its Cloud Next event. The announcements come days before Alphabet reports first-quarter earnings on April 29, with investors watching for signs that heavy AI and cloud spending will drive revenue growth.
FirstEnergy Ohio Rate Plan Could Add $4-$5 a Month to Bills as May 22 Filing Nears

FirstEnergy Ohio Rate Plan Could Add $4-$5 a Month to Bills as May 22 Filing Nears

23 April 2026
FirstEnergy’s Ohio utilities will file a three-year rate plan with state regulators by May 22, seeking to fund $800 million annually in grid upgrades and $83 million for tree trimming. The plan would raise monthly bills for typical 1,000-kWh households by $4.26 to $5.30 if approved. The filing follows recent rate cases by AES Ohio and AEP Ohio under the new House Bill 15 regime.
Salesforce stock slips as Momentum deal and UBS target cut put CRM in focus ahead of Feb. 25 earnings
Previous Story

Salesforce stock slips as Momentum deal and UBS target cut put CRM in focus ahead of Feb. 25 earnings

OCBC share price today: OCBC stock closes higher ahead of Feb 25 results
Next Story

OCBC share price today: OCBC stock closes higher ahead of Feb 25 results

Go toTop